الفهرس 
WHO classification of MDS 2016Only 14 pages are availabe for public view
 |  | from | 131 |  |  |
| | | from | 131 | | |
Abstract
Myelodysplastic syndrome (MDS) is a clonal disorder characterized initially by ineffective hematopoiesis and subsequently by frequent development of acute myelogenous leukemia (AML). Peripheral blood cytopenias in combination with a hypercellular bone marrow exhibiting dysplastic changes are the hallmark of MDS. For diagnosis, a bone marrow biopsy with aspirate to assess marrow cellularity, fibrosis, dysplasia, and topography is mandatory; flow cytometry and cytogenetics studies are also invaluable .A finding of excess blasts is supportive of MDS or an evolving acute leukemia. If extensive fibrosis is present, it may be more indicative of an MDS overlapping with a myeloproliferative neoplasm. Furthermore, the degree of dysplasia and the presence or absence of specific types of dysplasia are sometimes useful in distinguishing AA from hypoplastic MDS.
We aimed to review the clinical, hematological and histomorphological criteria of MDS patients in Delta region.